BioMarin Pharmaceutical Inc. Financials

Market Capitalization $11.85 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	37.46
Forward PE	20.80
Price to Sales TTM	$4.31
Price to Book MRQ	$2.19
Enterprise to Revenue	4.19
Enterprise to EBITDA	27.05

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	11.71%
Operating Margin	15.27%
Return on Assets TTM	3.00%
Return on Equity TTM	6.25%

Income Statement

Revenue TTM	$2,752,808,960
Revenue per Share TTM	$14.53
Quarterly Revenue Growth	28.30%
Gross Profit TTM	$1,441,218,048
EBITDA	$496,724,000
Net Income to Common TTM	$322,291,008
Diluted EPS TTM	$1.66
Quarterly Earnings Growth YoY	162.70%

Balance Sheet

Total Cash MRQ	$930,444,032
Total Cash per Share MRQ	$4.88
Total Debt MRQ	$
Total Debt to Equity MRQ	11.13
Current Ratio MRQ	4.27
Book Value per Share MRQ	$28.41

Cash Flow

Operating Cash Flow TTM	$414,696,992
Levered Free Cash Flow TTM	$144,674,752

BMRN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	190,583,008
Float Shares	179,186,152
Avg 10 Volume	2,072,010
Avg 30 Volume	None
Shares Short	4,542,138
Short Ratio	3.06
Short % of Shares	2.40%
% Held by Insiders	0.87%
% Held by Institutions	97.64%

Stock Price Summary

Beta	0.31
Fifty Two Week Low	$60.63
Fifty Two Week High	$94.85
Fifty Two Week Change	-48.68%
Day 50 MA	$65.24
Day 200 MA	$76.76

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date